Vaginal Rings and Microbicides
This presentation is the property of its rightful owner.
Sponsored Links
1 / 14

Vaginal Rings and Microbicides Mark Mitchnick, MD. October 30, 2007 PowerPoint PPT Presentation


  • 326 Views
  • Uploaded on
  • Presentation posted in: General

Vaginal Rings and Microbicides Mark Mitchnick, MD. October 30, 2007. Microbicide Delivery System Goals. Safe Effective Coitally Independent Daily Monthly Affordable Ease of manufacture Broadly stable Long shelf life Acceptable Versatile Forgiving PK Multiple actives.

Download Presentation

Vaginal Rings and Microbicides Mark Mitchnick, MD. October 30, 2007

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript


Vaginal rings and microbicides mark mitchnick md october 30 2007

Vaginal Rings and Microbicides

Mark Mitchnick, MD.

October 30, 2007


Microbicide delivery system goals

Microbicide Delivery System Goals

  • Safe

  • Effective

  • Coitally Independent

    • Daily

    • Monthly

  • Affordable

    • Ease of manufacture

    • Broadly stable

    • Long shelf life

  • Acceptable

  • Versatile

    • Forgiving PK

    • Multiple actives


Microbicide delivery choice will be key to widespread adoption of microbicides

Microbicide Delivery: Choice will be Key to Widespread Adoption of Microbicides

  • Diversity of delivery systems

    • Semisolids/Solids

      • Gels

      • Emulsions

      • Films

      • Tablets

    • Devices

      • Vaginal rings

      • Sponges

      • Physical barriers

    • Other?


Antiretroviral arv microbicides

Antiretroviral (ARV) Microbicides

  • Most developers are focusing on ARV’s

  • HIV specific

  • Highly active

  • Affordable

  • Can be formulated to be Coitally independent

  • Safe, lots of experience with most classes

  • Stable in relevant climatic zones


Microbicides in product development

Microbicides in Product Development

Lactin-V

Invisible Condom

Free virus

BufferGel

Carraguard

PRO2000

SPL7013 (VivaGel)

Monoclonal antibodies

DS003 (BMS)

DS001 (Merck)

DS006 (Maraviroc)

Attachment

Locus small molecules

Fusion

S-DABO

Dapivirine (TMC120)

UC781

Tenofovir (PMPA)

PC815 (MIV150 + Carraguard)

Pyrimidinediones (Samjin)

Replication

(RT)

Integration

Protein synthesis and assembly

Budding

Maturation


Ipm drug product grid medium term

IPM Drug Product Grid: Medium Term

  • Delivery Formats

    • Semisolids

      • Gels

      • Emulsions

      • Gel caps

    • Vaginal Rings

      • Matrix

      • Reservoir

    • Films

    • Dissolving Tablets

  • API

    • NNRTI

      • Dapivirine

    • NRTI

      • PMPA

    • R5 Blocker

      • Merck 167

      • Maraviroc (pending)

    • GP 120 binding

      • BMS 793


Dapivirine

Dapivirine

  • NNRTI developed by Tibotec/J&J, licensed to IPM (2004)

  • Developed originally as therapeutic, 11 clinical studies conducted via oral administration

  • Highly potent ARV

  • Low cytotoxicity, non-mutagenic, non-teratogenic

  • Easily manufactured, very cheap

  • Stable drug substance

  • IP clarity

  • Multiple dosage forms


Sustained release vaginal rings

Sustained Release: Vaginal Rings

  • Attractive technology:

    • 30+ days of drug delivery

    • Potentially reduces compliance burden

    • Easy to use

    • “Low” cost

  • Unknowns:

    • Acceptability in relevant populations

    • Scale up manufacture

    • Regulatory path in multiple countries

    • Feasibility of multi-drug combinations

    • Environmental impact


Addressing the unknowns

Addressing the Unknowns

  • Acceptability in relevant populations

    • Acceptability studies ongoing

  • Scale up manufacture

    • Survey of methods with scale-up of each investigated

    • Redundant capacity being installed

  • Regulatory path in multiple countries

    • Priority

    • Engaging regulators

  • Feasibility of multi-drug combinations

    • Multiple groups engaged to tackle

    • Several novel approaches

  • Environmental impact

    • Being quantified, primary concern is control over HIV

    • Additional matrix materials being investigated


Types of vaginal rings reservoir matrix

Types of Vaginal rings: Reservoir & Matrix

Dapivirine

Raman maps

Cross-sectional

profiles

Drug

Core-type

Matrix-type

Courtesy or Karl Malcolm, QUB


In vitro daily release of dapivirine from a silicone elastomer matrix vaginal ring

In-Vitro Daily Release of Dapivirine From a Silicone Elastomer Matrix Vaginal Ring

g Dapivirine

Days

-Sink conditions: Release medium is 50% IPA. Daily vaginal gel dose= 500 g (red line)


Human experience with vaginal rings to date

Human Experience with Vaginal Rings To Date

  • Several marketed products

    • Hormone releasing

    • FemRing

      • Vagianlmenapuse symptoms

      • Silicone reservoir

    • NuvaRing

      • Birth control

      • EVA reservoir

  • Microbicide containing rings

    • In development

    • Several Phase I studies

      • PK looking very promising

      • No safety issues to date


Dapivirine levels in clinical samples

Dapivirine Levels in Clinical Samples

EC50= 0.33 ng/mL

Dapivirine ng/mL

<50 pg/mL


Next steps

Next Steps

  • Complete manufacturing development

  • Install manufacturing capacity

  • Larger safety studies in 2008

  • Phase III study with Dapivirine ring in 2010

    • Part of larger multi-arm study

  • Strong efforts in additional development

    • Multiple actives in single ring

    • Additional Matrix materials


  • Login